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Abstract
Introduction The purpose of the present study was to evaluate the effects of continuously infused N-
acetyl-L-cystein (NAC) on serum cytokine levels and gastric intramucosal pH in humans suffering from
severe sepsis.
Methods Fifty-three patients were included in the study. In the NAC group (n = 27), after an initial
intravenous bolus of NAC (150 mg/kg over 5 min), a continuous intravenous infusion of 12.5 mg/kg
per hour was given for 6 hours. Patients in the control group (n = 26) were administered dextrose (5%
solution) at the same dosage. We recorded the following: haemodynamic parameters, nasopharyngeal
temperature, arterial blood gas changes, plasma cytokine levels, biochemical parameters, intramucosal
pH, length of stay in the intensive care unit, duration of of mechanical ventilation and mortality. All
measurements were taken at baseline (15 min before the start of the study) and were repeated
immediately after the bolus infusion, and at 24 and 48 hours after initiation of the continuous NAC
infusion.
Results No differences were found between groups in levels of the major cytokines, duration of
ventilation and intensive care unit stay, gastric intramucosal pH and arterial oxygen tension/inspired
fractional oxygen ratio (P > 0.05).
Conclusion We found that NAC infusion at the doses given did not affect cytokine levels, outcomes,
or gastric intramucosal pH in patients with severe sepsis. Because of the limited number of patients
included in the study and the short period of observation, our findings need confirmation in larger
clinical trials of NAC infused in a dose-titrated manner. However, our results do not support the use of
NAC in patients with severe sepsis.
Keywords: cytokine levels, gastric intramucosal pH, haemodynamic parameters, intensive care unit, N-acetyl-L-
cystein, severe sepsis
Introduction
Sepsis is defined as the systemic response to infection [1,2].
The deleterious effects of invasion of body tissues by bacteria
result from the combined actions of enzymes and toxins, pro-
duced both by the micro-organisms themselves and by endog-
enous cells in response to the infection. Patients with severe
infections have extremely low concentrations of protective
antioxidants and high levels of the metabolic products of free
radical damage, with the greatest increases seen in the most
severely ill [3,4].
N-acetyl-L-cysteine (NAC), a derivative of the naturally occur-
ring amino acid L-cysteine, is currently indicated for acute
paracetamol overdose [5]. Pharmacological actions include
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repletion of intracellular glutathione stores, scavenging of toxic
oxygen free radicals (both directly and indirectly via increased
glutathione concentrations) and suppression of tumour necro-
sis factor (TNF) production [6]. NAC may also exert a benefi-
cial effect on the oxidation and downregulation of essential
thiol groups in β-adrenergic receptors [7]. Furthermore, NAC
has been shown to decrease lipoperoxidative damage in early
clinical septic shock [8].
Gastric intramucosal pH (pHi) in experimental animals
decreases as splanchnic perfusion decreases below the level
at which local oxygen transport can no longer sustain aerobic
energy production [9]. Therefore, it may be possible to use pHi
as an early and noninvasive index of systemic tissue oxygena-
tion, given that selective reductions in splanchnic perfusion
occur with decreases in systemic oxygen transport [9].
The purpose of the present study was to evaluate the effects
of continuously infused NAC on serum cytokine levels and pHi
in humans suffering from severe sepsis.
Methods
Patient population and study design
The Regional Committee on Medical Research Ethics
approved the study. Written informed consent was obtained
from patients (wherever possible) or from the next of kin. Crit-
ically ill patients with bacteriologically documented infections
were included in the study as soon as they met at least two of
the following criteria for sepsis, as defined by the American
College of Chest Physicians/Society of Critical Care Medicine
Consensus Conference Committee [2]: temperature >38°C
or <36°C; heart rate >90 beats/min; respiratory rate >20
breaths/min or arterial carbon dioxide tension <32 mmHg; and
leucocyte count >12 × 109 cells/l or <4 × 109 cells/l. In addi-
tion, at least one of following conditions was required: hypox-
aemia (arterial oxygen tension/fractional inspired oxygen ratio
<250); oliguria (urine output <0.5 ml/kg body weight for 2
hours); lactic acidosis (lactate concentration >2 mmol/l);
thrombocytopenia (platelet count of <100 × 109/l); or a recent
change in mental status without sedation. Patients who were
under 18 years old, pregnant, or receiving corticosteroids,
immunosuppressants, or chemotherapy, and those with a
known irreversible underlying disease, such as end-stage neo-
plasm, were excluded.
The Acute Physiology and Chronic Health Evaluation II [10]
and Sepsis-related (or Sequential) Organ Failure Assessment
[11] scores were employed to determine the initial severity of
illness. If required, patients underwent surgical procedures
before the start of the study. No invasive surgery was per-
formed during the 48-hour study period. All patients were ven-
tilated in volume-controlled mode (Puritan Bennett 7200;
Puritan Bennett Inc., Carlsbad, CA, USA) and received contin-
uous analgesic sedation with midazolam and fentanyl. Ventila-
tor settings, and levels of positive end-expiratory pressure and
fractional inspired oxygen were kept constant during NAC or
placebo infusion. Antibiotic treatment was adjusted according
to the results of bacteriological culture (blood or or other sam-
ples). In all patients fluid replacement was administered to
keep the central venous pressure between 4 and 8 mmHg. No
inotropic agent was administered during the study. Those
patients who met the above criteria for severe sepsis were
enrolled in the study within 4 hours of intensive care unit (ICU)
admission.
Protocol
Randomization was done using a computer-steered permu-
tated block design. The study was prospective, randomized,
double blind and placebo controlled. In order to perform the
study in a double-blind manner, drug solution and infusion was
administered to all patients by a nurse without any knowledge
about the study protocol. Follow up was done by an anaesthet-
ist without any knowledge of the study protocol. Patients in the
NAC group (n = 27) were given NAC (ASIST®; Istanbul, Tur-
key; 300 mg/3 ml, 10%) as an intravenous bolus of 150 mg/
kg over 30 min, and then as a continuous intravenous infusion
of 12.5 mg/kg per hour for 6 hours. In the control group (n =
26), patients were given 5% dextrose as bolus and infusion
over 6 hours (same dosage).
A tonometer (TRIP NGS Catheter; Tonometrics Inc.,
Worchester, MA, USA) was inserted via the nasogastric route
before infusion of the bolus. The tonometer was advanced until
the balloon was located in the lumen of the stomach. The posi-
tion of the balloon was confirmed radiographically. The sili-
cone balloon of the tonometer was filled with 2.5 ml 0.9%
saline. After sufficient time for equilibration of carbon dioxide
tension between saline and the gastric lumen, anaerobic sam-
ples of the tonometer saline and of arterial blood were taken
simultaneously and analyzed using standard pH and blood gas
analyzers. pHi was calculated by a modification of the Hender-
son–Hasselbalch equation:
Where F is a time dependent factor for partly equilibrated sam-
ples provided by the manufacturer of the device.
Measurements
All patients had arterial catheters placed (arterial line kit, mon-
itoring kit transpac® IV; Abbott, Sligo, Ireland) and central
venous catheters via subclavian (Certofix trio V 720 7F × 8";
Braun, Melsungen, Germany). Arterial blood samples were
simultaneously withdrawn for measurements of pH, oxygen
and carbon dioxide tensions, and arterial oxygen saturation
(Easy BloodGas; Medica, MA, USA). Central venous pres-
sure, mean arterial pressure, heart rate and nasopharyngeal
temperature were continuously monitored (Model 90308,
SpaceLabs Inc., Redmond, WA, USA). All measurements
pHi
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were obtained at baseline (15 min before the start of the
study) and again after the bolus infusion, and at 24 and 48
hours after the start of the continuous infusion. Platelets, leu-
cocytes, bilirubin, alanine aminotransferase, and creatinine
were determined at the same times (Vitalab Flexor, Dieren, The
Netherlands).
TNF-α, IL-1β, IL-2 receptor, IL-6 and IL-8 levels were also
measured, at the time points indicated above. Venous blood
was collected into a 10 ml sterile plain tube (without anticoag-
ulant) before administration of any medications and stored at -
20°C. Before assay, all samples were thawed to room temper-
ature and mixed by gentle swirling or inversion. All sera were
assayed on the same day to avoid interassay variation. TNF-α,
IL-1, IL-2 receptor, IL-6 and IL-8 levels were measured using a
solid-phase, two-site chemiluminescent enzyme immunomet-
ric assay method (Immulite TNF-α, Immulite IL-1β, Immulite IL-
2 receptor, IL-6 Immulite and IL-8 Immulite; EURO/DPC, Llan-
beris, UK). The antibodies used in this procedure have no
known cross-reactivities with other cytokines. The lowest
detectable limits of IL-1β, IL-2 receptor, IL-6, IL-8 and TNF-α
were 1.5 pg/ml, 5 U/ml, 5 pg/ml, 2 pg/ml and 1.7 pg/ml,
respectively.
The duration of mechanical ventilation was recorded. Survival
was defined as being alive at hospital discharge.
Statistics
Repeated measures analysis of variance was used to evaluate
the differences between and within groups. If significant differ-
ences were present then the groups were tested by independ-
ent samples t-tests to determine which difference was
significant. Data are expressed as means ± standard devia-
tion. P < 0.05 was considered statistically significant.
Results
Patient characteristics
The clinical and demographic characteristics of the NAC and
control patients studied are summarized in Tables 1 and 2,
respectively. Of the 53 patients, 27 received NAC (NAC
group) and 26 received placebo (control group). Seventeen
patients had septic shock on admission (seven in the NAC
group, and 10 of the placebo-treated patients) and five died
while in the ICU for reasons unrelated to infection (pulmonary
embolism, cardiac death as determined by clinical and post-
mortem studies). Baseline Acute Physiology and Chronic
Health Evaluation II scores (13.14 ± 3.79 and 15 ± 3.58 for
the NAC and control groups, respectively) and Sepsis-related
Organ Failure Assessment scores (5.62 ± 2.52 and 6.53 ±
2.2 for the NAC and control groups, respectively) were similar
(P > 0.05). Infection was documented in all patients.
Haemodynamic parameters and oxygen transport 
variables
There were no significant differences between the groups with
respect to pH, oxygen tension, carbon dioxide tension, arterial
oxygen tension/fractional inspired oxygen ratio and arterial
oxygen saturation (P > 0.05). No significant change in mean
arterial pressure or heart rate was found in either group (Table
3). Also, there were no significant differences between the
groups in biochemical parameters (P > 0.05).
Outcome
Outcomes are listed in Tables 1 and 2. The overall hospital
mortality was 26% (seven patients) in the NAC group and
31% (eight patients) in the group control (P > 0.05). All of the
patients who died did so while they were being mechanically
ventilated. In the NAC and placebo groups, the durations of
mechanical ventilation were 8 ± 2 and 8 ± 3 days, respectively
(P > 0.05), and the numbers of ventilator-free days were 9 ±
3 and 8 ± 3, respectively (P > 0.05). The length of ICU stay of
NAC-treated survivors was not significantly different from that
of placebo-treated survivors (10 ± 2 days versus 11 ± 4 days;
P > 0.05).
Plasma cytokine levels
TNF-α, IL-1β, IL-2 receptor, IL-6 and IL-8 levels remained
unchanged during the study (Table 4).
Gastric intramucosal pH
There was no significant difference between the groups with
respect to pHi (P > 0.05; Table 4).
Side effects
The NAC infusion was well tolerated by all patients who
received it, and no side effects were noted during or after
administration of NAC.
Discussion
Systemic inflammatory response leading to postoperative
organ dysfunction and sepsis remains a formidable clinical
challenge and carries a significant risk for death. Recent clini-
cal studies suggest that patients with sepsis undergo relative
oxidative stress [12]. Overwhelming production of oxygen free
radicals is thought to play a central role in the inflammatory
process [3]. Many investigators have suggested that use of
exogenous agents such as NAC may be of benefit in prevent-
ing oxygen free radical damage in patients suffering from sep-
tic shock [13,14]. NAC acts as a powerful oxygen free radical
scavenger, and it replenishes depleted glutathione stores,
thus enhancing defence against endogenous antioxidants
[15].
Sepsis and septic shock remain major causes of death in
ICUs. Complications of sepsis result from an intense host
response caused by a disturbance of the delicate equilibrium
between various proinflammatory and anti-inflammatory medi-Critical Care    August 2004  Vol 8 No 4    Emet et al.
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ators [16]. Overwhelming production of proinflammatory
cytokines such as TNF-α, IL-1β, IL-2 receptor, IL-6 and IL-8
may induce biochemical and cellular alterations either directly
or by orchestrating secondary inflammatory pathways. NAC
can also exert important anti-inflammatory effects on neu-
trophills and monocytes [17]. Zhang and coworkers [13]
found that this decreased inflammatory response was
reflected by complete inhibition of TNF release with pretreat-
ment NAC. Peristeris and coworkers [6] demonstrated that
pretreatment with NAC significantly inhibited TNF production
both in serum and in spleen in a mouse model of endotoxae-
mia. This attenuating effect of NAC on TNF production is most
likely due to decreased release of oxygen free radicals. Fur-
thermore, in patients with sepsis who were administered NAC,
Paterson and coworkers [18] found decreased nuclear factor-
κB activation, which was associated with decreased levels of
IL-8 but not of IL-6 or soluble intercellular adhesion molecule-
1. That pilot study suggested that NAC may blunt the inflam-
matory response to sepsis by interfering with nuclear factor-
κB activation.
Spapen and colleagues [19] found that NAC had no signifi-
cant effect on plasma TNF, IL-6 or IL-10 levels, but acutely
decreased IL-8 and soluble TNF receptor/p55 levels. They
Table 1
Demographic and clinical characteristics of N-acetyl-L-cysteine treated patients
Patient Age (years) Sex Type of infection Pathogen Outcome
18 6 F P n e u m o n i a Pseudomomas aeruginosa Survived
25 4 F P n e u m o n i a Klebsiella pneumoniae1 Died (MOF)
35 2 F P n e u m o n i a Escherichia coli Survived
45 2 F P n e u m o n i a Staphylococcus aureus Survived
56 7 M P n e u m o n i a P. aeruginosa Survived
63 7 M P n e u m o n i a K. pneumoniae Died (MOF)
73 9 M P e r i t o n i t i s Enterococus faecalis Survived
87 0 M P e r i t o n i t i s S. aureus1 Survived
99 0 M P n e u m o n i a P. aeruginosa Survived
10 45 F Pneumonia S. aureus Survived
11 82 M Pneumonia E. faecalis1 Died (PE)
12 70 M Pneumonia P. aeruginosa Survived
13 82 M Pneumonia E. faecalis Survived
14 65 F Peritonitis E. coli1 Survived
15 80 M Pneumonia Streptococcus pneumoniae Died (PE)
16 72 M Pneumonia P. aeruginosa1 Survived
17 70 F Pneumonia E. faecalis Survived
18 70 F Peritonitis S. aureus Survived
19 70 M Pneumonia K. pneumoniae Died (CD)
20 62 F Pneumonia S. aureus Survived
21 55 M Pneumonia S. aureus1 Survived
22 70 F Peritonitis E. coli1 Survived
23 90 M Pneumonia E. faecalis Died (MOF)
24 65 F Pneumonia E. coli1 Survived
25 60 M Pneumonia S. pneumoniae Died (MOF)
26 65 F Pneumonia E. faecalis1 Survived
27 60 F Peritonitis E. faecalis, E. coli1 Survived
1Isolated from blood. CD, cardiac death; MOF, multiple organ failure; PE, pulmonary embolism.Available online http://ccforum.com/content/8/4/R172
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demonstrated that the attenuated production of IL-8 – a
potential mediator of septic lung injury – might have contrib-
uted to the lung protective effects of NAC.
In contrast to the findings of those studies, in the present study
we found that NAC infusion did not affect cytokine levels in
patients with severe sepsis. Cytokine levels in plasma do not
necessarily reflect local synthesis of cytokines by cells. Many
cells have surface receptors for these cytokines, with high
binding properties, and target cells and soluble receptors can
trap cytokines. Thus cytokines released locally may remain
undetected in plasma. In the present study we found that
plasma cytokine levels remained unchanged over a period of
48 hours. Spapen and coworkers [19] found that a short-term
(4 hour) infusion of NAC in patients with early diagnosed sep-
tic shock improved systemic oxygenation and static lung com-
pliance without influencing systemic and pulmonary
haemodynamics, and NAC-treated survivors had a less com-
plicated weaning period and a shorter length of stay in the ICU
than did the placebo-treated group. Spies and coworkers [14]
documented improvements in cardiac function, tissue oxygen-
ation and survival in patients in whom NAC (150 mg/kg intra-
venous bolus, followed by 18.75 mg over 90 min) increased
oxygen consumption. NAC improved lung compliance, chest
radiographic oedema score, and arterial oxygenation in
patients with acute respiratory distress syndrome (ARDS)
Table 2
Demographic and clinical characteristics of control patients
Patient Age (years) Sex Type of infection Pathogen Outcome
16 6 M P n e u m o n i a Enterococcus faecalis Died (MOF)
26 3 M P n e u m o n i a Pseudomonas aeruginosa1 Survived
3 67 M Peritonitis Staphylococcus aureus1 Survived
48 0 M P n e u m o n i a P. aeruginosa Survived
58 1 M P n e u m o n i a Escherichia coli Died (MOF)
65 7 M P n e u m o n i a E. coli Survived
7 67 M Peritonitis E. faecalis1 Survived
87 5 M P n e u m o n i a Klebsiella pneumoniae1 Died (PE)
96 7 M P n e u m o n i a Staphylococus aureus Survived
10 50 M Peritonitis E. faecalis1 Survived
11 50 F Pneumonia S. aureus1 Survived
12 78 M Pneumonia K. pneumoniae Survived
13 65 M Pneumonia E. faecalis Survived
14 50 M Peritonitis S. aureus1 Died (MOF)
15 63 M Pneumonia S. pneumoniae1 Died (CD)
16 45 F Pneumonia S. pneumoniae Survived
17 67 M Peritonitis E. coli1 Survived
18 91 K Pneumonia S. aureus Survived
19 30 M Peritonitis E. faecalis1 Survived
20 59 M Pneumonia S. pneumoniae Died (MOF)
21 69 M Pneumonia S. pneumoniae Survived
22 71 M Peritonitis S. aureus1 Survived
23 58 M Pneumonia E. coli1 Died (MOF)
24 46 F Peritonitis E. faecalis1 Survived
25 66 M Pneumonia E. faecalis, E. coli Survived
26 71 M Pneumonia K. pneumoniae Died (MOF)
1Isolated from blood. CD, cardiac death; MOF, multiple organ failure; PE, pulmonary embolism. [AU: for patient number 9, please define 'Sf' in 
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[20]. Recently, prolonged infusion of NAC (70 mg/kg for 10
days) was found to improve cardiac function and to attenuate
lung injury in patients with ARDS [21].
Despite these encouraging findings, the role of NAC in criti-
cally ill remains controversial. Recent randomized, placebo-
controlled studies found no significant differences between
NAC and placebo in gas exchange, development of ARDS,
and mortality in patients with ARDS and early septic shock
[22,23]. Furthermore, several papers reported conflicting and
undesirable effects of NAC administration. For example,
Peake and coworkers [24] treated patients with a different
NAC infusion scheme (150 mg/kg intravenous bolus, followed
by 50 mg/kg over 4 hours, and then 100 mg/kg per 24 hours
for 44 hours) and found significant depression of cardiovas-
culer performance after 24 hours, together with increased
mortality. In the present study we found that NAC infusion had
no effect on the cardiovascular and pulmonary systems in
patients with severe sepsis. However, the study was designed
to assess the effects of NAC treatment given before septic
shock but after the development of the systemic inflammatory
response syndrome. For this reason no serious cardiovascular
and pulmonary system problems were encountered in the
patients studied.
Oxygen radical scavengers, administered before or at the
onset of sepsis, were shown to improve survival in animal mod-
els of sepsis [25]. NAC was shown to enhance oxygen con-
sumption via increased oxygen extraction in patients 18 hours
after the onset of fulminant liver failure [26]. Spies and cowork-
ers [14] demostrated that NAC provided a transient improve-
ment in tissue oxygenation in about half of a group of patients
with septic shock, and they identified increased whole body
oxygen consumption and pHi, and decreased veno-arterial
carbon dioxide tension. Those investigators also found a
higher survival rate in NAC responders, and half of the patients
receiving NAC did not respond; they suggested that, in some
patients, sepsis irreversibly damages the microvasculature,
Table 3
Hemodynamic, oxygen and temperature variables
Variable Baseline Immediately after NAC 
infusion
24 hours after NAC 
infusion
48 hours after NAC 
infusion
Heart rate (beats/min)
NAC 110.88 ± 25.9 113.00 ± 25.4 112.74 ± 22.4 108.70 ± 22.2
Control 104.84 ± 18.2 105.19 ± 23.5 105.23 ± 23.5 103.15 ± 22.7
Mean arterial pressure (mmHg)
NAC 90.85 ± 16.67 88.92 ± 13.01 86.07 ± 13.21 85.96 ± 13.41
Control 91.26 ± 18.25 83.80 ± 14.77 85.42 ± 13.42 83.80 ± 11.31
Arterial pH
NAC 7.34 ± 0.10 7.41 ± 0.07 7.38 ± 0.10 7.39 ± 0.06
Control 7.35 ± 0.09 7.38 ± 0.07 7.39 ± 0.08 7.36 ± 0.08
Arterial carbon dioxide tension (mmHg)
NAC 35.88 ± 12.7 34.62 ± 18.8 35.00 ± 14.2 38.54 ± 15.1
Control 31.69 ± 20.1 38.56 ± 20.2 36.46 ± 71.13 34.33 ± 21.6
Arterial oxygen tension/fractional inspired oxygen ratio (mmHg)
NAC 172 ± 88 176 ± 76 178 ± 81 179 ± 126
Control 174 ± 76 177 ± 65 181 ± 70 179 ± 68
Arterial oxygen saturation (%)
NAC 96.1 ± 3.4 95.1 ± 3.7 95.2 ± 3.8 95.6 ± 4.2
Control 95.9 ± 3.5 95.0 ± 4.1 94.8 ± 3.2 95.1 ± 3.6
Temperature (°C)
NAC 36.8 ± 0.75 37 ± 0.78 36.8 ± 0.75 36.9 ± 0.48
Control 36.6 ± 0.57 36.8 ± 0.45 36.6 ± 0.57 36.8 ± 0.53
Data are expressed as mean ± standard deviation. We identified no statistically significant differences between groups. NAC, N-acetyl-L-cysteine.Available online http://ccforum.com/content/8/4/R172
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which would account for the lack of effect of NAC in some
patients. In the present study, we found that NAC infusion did
not affect pHi in severe sepsis in humans.
In the present study we identified no positive effects of NAC.
We were unable to detect differences in systemic oxygena-
tion, ventilatory requirements, or mortality rate in NAC-treated
patients, as reported by Szakmany and coworkers [22] and by
Domenighetti and colleagues [23]. We also found that NAC
infusion did not affect biochemical parameters in patients with
severe sepsis, as reported by Szakmany and coworkers [22].
Vomiting and diarrhoea are the side effects most commonly
experienced with NAC. Other reported side effects include
increased blood pressure, chest pain, hypotension, rectal
bleeding, respiratory distress, headache, lethargy, fever and
skin allergy [27]. We did not encounter these side effects in
the present study.
We found that NAC infusion (150 mg/kg intravenous bolus,
followed by intravenous infusion at 12.5 mg/kg per hour for 6
hours) did not affect cytokine levels, patient outcomes, or pHi
in severe sepsis in humans. From the literature it appears that
Table 4
APACHE II and SOFA scores, cytokine levels, gastric intramucosal pH and gastric intramucosal carbon dioxide tension
Variable Baseline Immediately after NAC 
infusion
24 hours after NAC 
infusion
48 hours after NAC 
infusion
APACHE II score
NAC 13.14 ± 3.79 - 13.33 ± 3.83 12.74 ± 3.87
Control 15 ± 3.58 - 15.34 ± 3.30 15.69 ± 3.4
SOFA score
NAC 5.62 ± 2.52 5.55 ± 2.04 5.48 ± 2.57 5.48 ± 2.7
Control 6.53 ± 2.2 6.92 ± 2.59 7.15 ± 2.9 7.15 ± 2.86
Tumour necrosis factor-α (pg/ml)
NAC 25.58 ± 15.8 26.02 ± 16.1 22.68 ± 13.9 28.17 ± 26.8
Control 22.57 ± 28.2 24.90 ± 13.56 25.05 ± 21.8 28.25 ± 24.3
IL-1β (pg/ml)
NAC 6.68 ± 1.85 6.38 ± 1.07 5.91 ± 1.26 5.57 ± 1.62
Control 5.35 ± 1.32 5.09 ± 0.30 5.34 ± 1.01 5.11 ± 0.58
IL-2 receptor (U/ml)
NAC 1847 ± 1366 1918 ± 1450 1829 ± 1427 1816 ± 1806
Control 2288 ± 1503 2372 ± 1531 2382 ± 1599 2168 ± 843
IL-6 (pg/ml)
NAC 100.26 ± 88 100.22 ± 19.8 110.51 ± 37 100.38 ± 38
Control 115.85 ± 85 115.64 ± 19.8 113.86 ± 27 119.48 ± 38
IL-8 (pg/ml)
NAC 161.50 ± 55 161.6 ± 10.3 162.1 ± 12.4 168.8 ± 113
Control 172.95 ± 27 163.3 ± 28.4 169.6 ± 28.6 171.0 ± 31
Gastric intramucosal pH
NAC 8.41 ± 0.21 8.43 ± 0.22 8.43 ± 0.17 -
Control 8.26 ± 0.18 8.31 ± 0.16 7.45 ± 0.47 -
Gastric intramucosal carbon dioxide tension (mmHg)
NAC 67.2 ± 20.1 70.2 ± 15.6 69.0 ± 21.9 -
Control 68.7 ± 22.8 69.7 ± 23 68.9 ± 25.7 -
Data are expressed as means ± standard deviation. APACHE, Acute Physiology and Chronic Health Evaluation; IL, interleukin; NAC, N-acetyl-L-
cysteine; SOFA, Sepsis-related Organ Failure Assessment.Critical Care    August 2004  Vol 8 No 4    Emet et al.
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lower doses of NAC are associated with favourable haemody-
namic but no immunomodulatory effects [14] whereas higher
doses do influence cytokine production but may cause cardi-
ovascular dysfunction [13,19,24]. Because of the limited
number of patients included and the short period of observa-
tion, our findings require confirmation in larger clinical trials of
NAC infused in a dose-titrated manner. However, our findings
do not support the use of NAC in patients with severe sepsis.
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Key messages
NAC administration had no statistically significant effects 
on serum cytokine levels and pHi. We identified no 
adverse effects assoaicted with infusion of NAC.
On the basis of our findings, there appears to be no role 
for NAC in patients with severe sepsis.